The new funds will be used to drive Us2.ai’s ambitious growth targets for clinical implementation in the US, Europe and Asia
Us2.ai, the Singapore-based medtech developers of FDA-cleared AI software announced it has raised $15 million in a series A round led by IHH Healthcare and Heal Partners, with participation from Pappas Capital and existing investors including Sequoia India, EDBI and Partech Ventures.
The new funds will be used to drive Us2.ai’s ambitious growth targets for clinical implementation in the US, Europe and Asia, as well as the expansion of commercial activities with leading pharmaceutical companies, research labs, and imaging providers worldwide.
James Hare, CEO and co-founder, Us2.ai. “Our software automatically processes full echocardiographic studies of 2D and Doppler images from any vendor, in less than two minutes, delivering complete echo reports, with fully explainable measurements, editable annotations and conclusions for every chamber of the heart.”
“Us2.ai will increase patient access to echocardiography by providing a unique AI solution that completely automates the reading of studies, with accuracy comparable to experts, yet over 30 times faster; leaving doctors in full control and with more time to spend with patients,” said Dr Carolyn Lam, Senior Consultant Cardiologist at National Heart Centre Singapore, Professor at Duke-National University of Singapore and co-founder of Us2.ai.
Us2.ai has completed multiple projects with global pharmaceutical partners as well as a ground breaking approval study at the Brigham & Women’s Hospital. Their patented software workflow was recently described in Lancet Digital Health, where external validation was demonstrated in large, diverse, real world patient studies globally.
Dr Kelvin Loh, MD and CEO, IHH stated, “Through investments in innovative digital health companies like Us2.ai, we seek to support and make cutting-edge clinical tools and care (in this case AI-powered echocardiogram analysis) more accessible and affordable for patients, and enhance the delivery of care by doctors. This will speed up the diagnosis of heart conditions for the public.”
